摘要
目的探讨吉非替尼治疗晚期非小细胞肺癌临床疗效及安全性。方法将56例晚期非小细胞肺癌患者随机分为观察组和对照组各28例,观察组给予吉非替尼口服治疗,对照组给予吉西他滨联合顺铂治疗,观察两组临床疗效、症状改善情况及毒副反应情况。结果两组有效率比较,无显著差异,观察组临床受益率明显高于对照组,组间比较有显著差异(P<0.05);观察组症状改善情况优于对照组,组间比较有显著差异(P<0.05);观察组贫血、中性粒细胞减少、血小板减少及恶心呕吐的发生率明显低于对照组,组间比较有显著差异(P<0.05);观察组皮疹和腹泻的发生率明显高于对照组,组间比较有显著差异(P<0.01)。结论吉非替尼治疗晚期非小细胞肺癌具有疗效好、症状改善明显、毒副反应小等特点,是目前治疗非小细胞肺癌的一种较佳化疗药物,值得临床推广应用。
Objective To investigate clinical efficacy and safety of gefitinib treatment to advanced non-small cell lung cancer.Method 56 patients with advanced non-small cell lung cancer were randomly divided into two groups and a control group of 28 patients,observation group received oral gefitinib treatment,the control group received gemcitabine and cisplatin.Clinical efficacy,symptom improvement conditions and adverse reactions.were observed.Results There were no significant differences on clinical efficency between 2 groups,the clinical benefit rate of observation group was significantly higher than those of control group（P0.05）;Symptom improvement of observation group was better than those in control group（P0.05）;Adverse reactions such as anemia,neutropenia,thrombocytopenia and nausea and vomiting were significantly lower than the control group（P0.05）;The incidence of rash and diarrhea was significantly higher in observation group（P0.01）.Conclusion Gefitinib treatment on advanced non-small cell lung cancer has better efficacy,improved symptoms and less toxicity,which is a better chemotherapy drugs in the treatment of non-small cell lung cancer,worthy of clinical application.
出处
《肿瘤药学》
CAS
2011年第6期511-513,共3页
Anti-Tumor Pharmacy
